Quality of life and adherence to therapy in patients with chronic myeloid leukemia treated with nilotinib as a second line therapy: a multicener prospective observational study

To evaluate quality-of-life (QOL) and adherence to Nilotinib used as a second line therapy in 177 chronic myeloid leukemia patients in chronic phase a multicenter, prospective observational study was conducted. The QOL was very good and adherence to the treatment was high. Study results could be taken into consideration in the process of TKI treatment choice

Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Tomasz Sacha, Joanna G óra-Tybor, Ewa Wąsak-Szulkowska, Sławomira Kyrcz-Krzemień, Ewa Mędraś, Rafał Becht, Grażyna Bober, Aneta Kotowska, Joanna Wącław, Andrzej Hellmann Tags: Original Study Source Type: research